CLINICAL TRIAL AGREEMENTClinical Trial Agreement • January 23rd, 2013
Contract Type FiledJanuary 23rd, 2013PROTOCOLNUMBER D699BC00001 PROTOCOL TITLE A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg asHormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy (FALCON) PROTOCOL DATE 1 May 2012 SPONSOR Astra Zeneca AB, 151 85 Södertälje, Sweden PRINCIPAL INVESTIGATOR Branislav Bystricky, M. D.“an employee of Institution”